オプションチェーンは、Sight Sciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Sight Sciencesの市場センチメントを評価します。.

Sight Sciences (NASDAQ:SGHT) 株価情報, オプションチェーン

Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Sight Sciences Inc

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. The company reported quarterly sales of $709.00 million which missed the analyst consensus estimate of $717.66 million by 1.21 percent. This is a 12.84 percent increase over sales of $628.34 million the same period last year.

Earnings

Earnings Misses

News

EXAS

Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $62.400 million which beat the analyst consensus estimate of $58.025 million by 7.54 percent. This is a 152.63 percent increase over sales of $24.700 million the same period last year.

Earnings Beats

NCMI

National CineMedia Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $62.400M Beat $58.025M Estimate

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) lowers FY2025 sales outlook from $450.00 million-490.00 million to $430.00 million-470.00 million vs 458.78M analyst estimates.

Guidance

AVNW

Aviat Networks Lowers FY2025 Sales Guidance from $450.00M-490.00M to $430.00M-470.00M vs 458.78M Est.

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 3.95 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $33.251 million which beat the analyst consensus estimate of $32.517 million by 2.26 percent. This is a 47.76 percent increase over sales of $22.504 million the same period last year.

RYTM

Rhythm Pharmaceuticals Q3 2024 GAAP EPS $(0.73) Beats $(0.82) Estimate, Sales $33.251M Beat $32.517M Estimate

Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. The company reported quarterly sales of $167.900 million which missed the analyst consensus estimate of $171.192 million by 1.92 percent. This is a 4.01 percent decrease over sales of $174.909 million the same period last year.

CRCT

Cricut Q3 2024 Adj. EPS $0.05, Inline, Sales $167.900M Miss $171.192M Estimate

Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $1.33 by 17.29 percent. This is a 3.31 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $153.87 million which beat the analyst consensus estimate of $150.70 million by 2.10 percent. This is a 8.36 percent increase over sales of $142.00 million the same period last year.

QLYS

Qualys Q3 2024 Adj EPS $1.56 Beats $1.33 Estimate, Sales $153.87M Beat $150.70M Estimate

PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $15.256 million which beat the analyst consensus estimate of $14.822 million by 2.93 percent. This is a 23.03 percent increase over sales of $12.400 million the same period last year.

PAYS

PaySign Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $15.256M Beat $14.822M Estimate

RARE

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

Share Repurchase Program:
The Company's board of directors (the "Board") has approved a new share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company is authorized to repurchase up to $100.0 million in shares of the Company's common stock, inclusive of fees and commissions. This program replaces the Company's previous share repurchase program adopted in 2021, under which $9.4 million remained available for repurchase. The 2024 Share Repurchase Program is effective immediately and does not have an expiration date.
Repurchases under the 2024 Share Repurchase Program may be made, from time to time, in amounts and prices the Company deems appropriate and may be made pursuant to a trading plan intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases by the Company under the 2024 Share Repurchase Program will be subject to general market and economic conditions, applicable legal requirements and other considerations. The 2024 Share Repurchase Program may be suspended, modified or discontinued by the Board at any time without prior notice at the Company's discretion.

Buybacks

Grocery Outlet Holding Corp. Has Approved A New Share Repurchase Program Pursuant To Which The Company Is Authorized To Repurchase Up To $100M In Shares Of The Company's Common Stock,

Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.221 billion which Beat the analyst consensus estimate. This is a 11.54 percent decrease over sales of $3.64 billion the same period last year.

LUMN

Lumen Technologies Q3 2024 Adj EPS $(0.13) Misses $(0.09) Estimate, Sales $3.221B Beat $3.218B Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.18) by 144.44 percent. The company reported quarterly sales of $854.000 thousand which missed the analyst consensus estimate of $6.477 million by 86.81 percent. This is a 24.85 percent increase over sales of $684.000 thousand the same period last year.

EOSE

Eos Energy Enterprises Q3 2024 Adj. EPS $(0.44) Misses $(0.18) Estimate, Sales $854.000K Miss $6.477M Estimate

Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the <a href="https://www.zacks.com/education/stock-style-scores/momentum-trading" target="_blank">Zacks Style Scores</a>, helps address this issue for us.
Below, we take a look at U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. U.S. Bancorp currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
<h3>Set to Beat the Market?</h3>
In order to see if USB is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this company holds up.
Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For USB, shares are up 0.21% over the past week while the Zacks Banks - Major Regional industry is up 0.33% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.12% compares favorably with the industry&#39;s 4.51% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of U.S. Bancorp have risen 13.79%, and are up 33.8% in the last year. On the other hand, the S&amp;P 500 has only moved 7.29% and 32.85%, respectively.
Investors should also pay attention to USB&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. USB is currently averaging 8,694,755 shares for the last 20 days.
<h3>Earnings Outlook</h3>
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with USB.
Over the past two months, 6 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost USB&#39;s consensus estimate, increasing from $3.86 to $3.92 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 1 downward revision in the same time period.
<h3>Bottom Line</h3>
Given these factors, it shouldn&#39;t be surprising that USB is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep U.S. Bancorp on your short list.
<a href="https://www.zacks.com/stock/news/2364640/u-s-bancorp-usb-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2364640">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Markets

Trading Ideas

General

U.S. Bancorp Is A Great Momentum Stock: Should You Buy?

Contracts

Eos Energy Announced A New Agreement With City Utilities To Provide 216 MWh Of Energy Storage For Two Project Sites In Missouri: Terms Not Disclosed

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) sees Q4 sales of $82.000 million-86.000 million vs $89.27 million estimate.

National CineMedia Sees Q4 Sales $82.000M-86.000M vs $89.27M Est.

Outlook:
The Company is updating key guidance figures for fiscal 2024 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previous</td>
<td>Current</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New store openings, net(2)</td>
<td>62 to 64</td>
<td>66</td>
</tr>
<tr>
<td>Net sales</td>
<td>$4.30 billion to $4.35 billion</td>
<td>slightly above $4.35 billion</td>
</tr>
<tr>
<td>Comparable store sales increase</td>
<td>~3.5%</td>
<td>~2.4%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>~30.5%</td>
<td>~30.4%</td>
</tr>
<tr>
<td>Adjusted EBITDA(1)</td>
<td>$252 million to $260 million</td>
<td>$237 million to $242 million</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share(1)</td>
<td>$0.89 to $0.95</td>
<td>$0.77 to $0.80</td>
</tr>
<tr>
<td>Capital expenditures (net of tenant improvement allowances)</td>
<td>~$200 million</td>
<td>~$200 million</td>
</tr>
</tbody>
</table>
</figure>

Grocery Outlet Holding Corp. Updates FY24 EPS Guidance From $0.89-$0.95 To $0.77-$0.80 Vs $0.88 Est.; Revenue From $4.30B-$4.35B To Slightly Above $4.35B Vs $4.37B Est.

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) reported quarterly earnings of $0.02 per share. This is a 230.77 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $56.00 million which missed the analyst consensus estimate of $57.30 million by 2.28 percent. This is a 10.60 percent increase over sales of $50.63 million the same period last year.

VTEX

Vtex Q3 EPS $0.02 Up From $(0.01) YoY, Sales $56.00M Miss $57.30M Estimate

Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.53) by 8.5 percent. The company reported quarterly sales of $139.494 million which beat the analyst consensus estimate of $135.794 million by 2.72 percent. This is a 42.27 percent increase over sales of $98.052 million the same period last year.

Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate

United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.33 by 145.45 percent. The company reported quarterly sales of $322.964 million which beat the analyst consensus estimate of $306.800 million by 5.27 percent. This is a 17.89 percent increase over sales of $273.955 million the same period last year.

UFCS

United Fire Gr Q3 2024 Adj. EPS $0.81 Beats $0.33 Estimate, Sales $322.964M Beat $306.800M Estimate

On a day when global attention focused on the U.S. presidential election, Israeli Prime Minister Benjamin Netanyahu announced the dismissal of defense minister Yoav Gallant, amid a crisis of trust over differences in managing <a href="https://www.benzinga.com/topic/israel-hamas-war">Israel's war efforts in Gaza</a>.
Gallant, who had held the defense minister post since 2022, has been a key figure in Israel&#8217;s response to the ongoing conflicts against Hamas and Iran-backed Hezbollah. 
According to Netanyahu&#8217;s remarks, the relationship between the two deteriorated in recent months, fueled by what the prime minister described as significant gaps in their approach to the war effort.
See Also: <a href="https://www.benzinga.com/news/24/10/41348633/emmanuel-macron-has-sharp-words-for-israels-pm-mr-netanyahu-must-not-forget-that-his-country-was-cre">Emmanuel Macron Has Sharp Words For Israel&#8217;s PM: &#8216;Mr. Netanyahu Must Not Forget That His Country Was Created By A UN Decision&#8217;</a>
"I tried to bridge these gaps, but they kept getting wider," Netanyahu said in a statement. He argued that the trust issues had become "public domain," a development that he claimed was exploited by Israel's adversaries. 
Gallant, for his part, responded to the firing on X, formerly known as Twitter. He expressed unwavering commitment to Israel's safety.
"The security of the State of Israel was and will always remain the mission of my life," he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">ביטחון מדינת ישראל היה ותמיד יישאר משימת חיי &#x1f1ee;&#x1f1f1;&#x1f1ee;&#x1f1f1;
&mdash; יואב גלנט &#8211; Yoav Gallant (@yoavgallant) <a href="https://twitter.com/yoavgallant/status/1853862189888602366?ref_src=twsrc%5Etfw">November 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In place of Gallant, Netanyahu has appointed Israel Katz, a seasoned politician who has held multiple cabinet positions, including minister of foreign affairs, minister of finance, and minister of intelligence.
&#8220;He is known as a bulldozer with a combination of responsibility and firmness, quiet firmness, and all of these are very important for managing the campaign,&#8221; Netanyahu said about Katz.
Additionally, Netanyahu revealed discussions with minister without portfolio Gideon Sa'ar, inviting him to join the coalition as Foreign Minister.
<h3 class="wp-block-heading">Market Reactions: Oil, Israeli Stocks Rise</h3>
News of Gallant's dismissal and the internal discord in Israel's wartime leadership had a marginal impact on financial markets, with traders fully focused on the upcoming results from U.S. elections. 
West Texas Intermediate (WTI) light crude, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), was 0.6% up to $72.2 a barrel as of 3:10 p.m. ET on Tuesday, holding earlier gains during the session and marking its second consecutive day in the green.
Israeli stocks saw a slight boost Tuesday, with the VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>) climbing 0.8%.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41753325/wall-street-rallies-on-election-day-palantir-skyrockets-bitcoin-tops-70-000-whats-driving-">Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image: Shutterstock

Emerging Markets

Emerging Market ETFs

Commodities

Politics

ETFs

ISRA

Israel's Netanyahu Fires Defense Minister Gallant Over Lack Of Trust in War Management, Oil Prices Rise As Election Results Loom

MariMed (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.
Analysts estimate that MariMed will report an earnings per share (EPS) of $-0.01. 
MariMed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 3.43% increase in the share price the following trading session.
Here's a look at MariMed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.01</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>0</td>
<td>0.004</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730840556_0.png" alt="eps graph" />
<h3>Performance of MariMed Shares</h3>
Shares of MariMed were trading at $0.1629 as of November 04. Over the last 52-week period, shares are down 49.97%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MRMD/earnings">To track all earnings releases for MariMed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRMD

Exploring MariMed's Earnings Expectations

Sight Sciences (SGHT) just unveiled an announcement. Sight Sciences has made their latest investor presentation available on their website, signali...

Sight Sciences Unveils Investor Presentation for Future Talks

Needham analyst David Saxon has maintained their neutral stance on SGHT stock, giving a Hold rating on July 17. David Saxon's rating is based on a ...

Hold Rating on SGHT Amid Balanced Prospects and Pricing Concerns

Sight Sciences (SGHT) Gets a Hold from Piper Sandler

Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Sight Sciences (SGHT – Research Report) today and set a price target of $7.00....

Morgan Stanley Sticks to Their Hold Rating for Sight Sciences (SGHT)

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Frank Takkinen, an analyst from Lake Street, has initiated a new Buy rating on Sight Sciences (SGHT). Frank Takkinen has given his Buy rating due t...

Sight Sciences Poised for Growth: Buy Rating Affirmed Amid Market Expansion and Favorable Reimbursement Outlook

Analyst Kallum Titchmarsh of Morgan Stanley maintained a Hold rating on Sight Sciences (SGHT – Research Report), retaining the price target of $7.0...

Sight Sciences: A Balanced View Amidst Recovery and Uncertainties

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioventus (BVS – Research Report), Sight Sciences (S...

Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Sight Sciences (SGHT)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Sight Sciences (SGHT – Research Report), with a price target...

Lake Street Keeps Their Buy Rating on Sight Sciences (SGHT)

Lake Street analyst Frank Takkinen reiterated a Buy rating on Sight Sciences (SGHT – Research Report) today and set a price target of $10.00. The c...

Lake Street Sticks to Its Buy Rating for Sight Sciences (SGHT)

ATEC

SGHT

Press Releases

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

Sight Sciences Announces the Release of its First Sustainability Report

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Comments

Sight Sciences

Sight Sciences (SGHT) オプション

Sight Sciences (NASDAQ:SGHT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル